Global Markets Archives - Page 7 of 41 - BioProcess InternationalBioProcess International

Boosters and beyond: CDMOs likely to continue to ride COVID-19 wave

Inoculating children and booster jabs will further fuel CDMO demand argues GlobalData’s Fiona Barry, who adds industry’s reliance on third-party manufacturers will not abate post-pandemic. Since the start of the pandemic, biopharma’s efforts and determination in developing and producing billions of vaccines and therapeutics have led to some companies and sectors benefitting from a COVID-19 windfall. The contract development and manufacturing organization (CDMO) sector is one such group, with both drug substance and drug product capacity proving crucial in the…

Moderna lays plans for $500m African mRNA plant

by Dan Stanton

Details remain under wraps, but the $500 million investment will lead to Moderna’s first biomanufacturing facility outside of North America. Moderna, which sprang to the forefront of biopharma on the back of the success of its COVID-19 vaccine, announced yesterday it will invest up to $500 million into a facility on the African continent to support production of its messenger RNA portfolio. While the exact location (Africa is a big place!) has not yet been decided, a spokesperson for the…

CDMO BioCina rises out of Pfizer’s Australian ashes

by Dan Stanton

Bridgewest Group has launched BioCina, a microbial therapy and mRNA-based manufacturer operating from a former Pfizer facility in Adelaide, Australia. Last year, Bridgewest Australia Holdings, a subsidiary of private investment firm Bridgewest Group, entered the biologics production space by inking a deal to acquire a Pfizer plant in Adelaide, Australia. This week, the company has completed an expansion program and relaunched the 60,000 square-foot site under its contract development and manufacturing organization (CDMO) banner BioCina. The Adelaide site now includes…

BioProcess Insider State of the Industry — September 2021 Panel Discussion

by BPI Staff

Our BioProcess Insider editorial team sits down with Joshua Speidel, PhD Partner, Latham Biopharm Group, Patrick Lucy, President and CEO, Lykan Biosciences, and Amélie Boulais, Head of Market Entry Strategy, Virus Based Therapeutics at Sartorius, to reflect on how the quarterly movements of the wider pharma industry are affecting the biomanufacturing space. Through the analysis of global events, recent deal making, and regulatory and technological advancements, we look to determine the factors driving or squeezing production and pre-empt upcoming trends…

Chinese CDMO market growing rapidly despite talent shortage, says Lonza

by Millie Nelson

Lonza says its presence in China is growing despite a short-term talent shortage in the industry. “The Chinese pharma market is big and growing very quickly [with] a lot of molecules that are in development,” Lonza’s general manager of China, Hong Pan, tells BioProcess Insider. “China was very generically driven but more companies are putting their money into innovative pharma. The added growth is due to a few factors, [such as] the increased wealth of the population. People are getting…

Biocon jumps into vaccines through $4.9bn Serum Institute pact

by Dan Stanton

The strategic alliance will see Biocon access a minimum of 100 million doses of vaccines per year from Serum Insititute’s facility in Pune, India. The two Indian biopharma giants announced Friday a strategic alliance to complement each other’s vaccine and biologics capabilities and manufacturing capacity. “This alliance will complement the strengths and resources of the two leading players in vaccines and biologics,” Biocon’s executive chair Kiran Mazumdar-Shaw said. “Our shared vision of building large scale businesses having global impact makes…

Cytiva makes good on China single-use expansion

by Dan Stanton

Plans to triple single-use component production in China through a longstanding partnership with Wego Pharmaceutical are well underway, says Cytiva. Wego Pharmaceutical Co.’s Weihai, China facility makes single-use bioprocessing consumables on behalf of Cytiva after the two firms forged a partnership in November 2018. The site will expand its capacity through plans envisaged last September but announced last week. “Three new manufacturing lines were launched in under ten months with an additional eight new lines planned to launch in Q3…

Eli Lilly and industry criticize Biden’s drug pricing plan

by Dan Stanton

Eli Lilly says the US Government’s latest pricing plan will restrict access of drugs to patients and restrict industry innovation. On Thursday, the US Department of Health and Human Services published a plan to address what it describes as prices for prescription drugs that are “higher than any comparable nation.” The report is based on three guiding principles for drug pricing reform: 1) To make drug prices more affordable and equitable for all consumers and throughout the health care system…

COVID-19 boosters set to bolster life sciences services firms

by Dan Stanton

With booster shots on the agenda, large life sciences vendors and contract manufacturers are likely to see the COVID-19 windfall continue for the foreseeable future. It has only been nine months since vaccines began being rolled out to combat COVID-19, but some countries are now administering, or planning to administer, third shots to vulnerable patients. Nearly a million Americans have already received a booster shot, while a third dose of Pfizer/BioNTech’s vaccine is becoming part and parcel of Israel’s immunization…

WuXi’s ongoing capacity drive ups planned MA investment to $300m

by Dan Stanton

WuXi Biologics is expanding bioreactor capacity at its site in Worcester, Massachusetts from 6,000 L to 24,000 L to support demand for biomanufacturing onshoring. Plans for a first US facility were drawn up by China-headquartered contract development and manufacturing organization (CDMO) WuXi Biologics in 2018, with construction beginning in Worcester two years later. But after winning planning approval from the local council last week, WuXi Biologics will expand the site, quadrupling bioreactor single-use capacity through an additional $235 million of…